[go: up one dir, main page]

PA8552301A1 - Metodo para el tratamiento de insomnio primario - Google Patents

Metodo para el tratamiento de insomnio primario

Info

Publication number
PA8552301A1
PA8552301A1 PA20028552301A PA8552301A PA8552301A1 PA 8552301 A1 PA8552301 A1 PA 8552301A1 PA 20028552301 A PA20028552301 A PA 20028552301A PA 8552301 A PA8552301 A PA 8552301A PA 8552301 A1 PA8552301 A1 PA 8552301A1
Authority
PA
Panama
Prior art keywords
treatment
primary insomnia
primary
agents
melatonist
Prior art date
Application number
PA20028552301A
Other languages
English (en)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11075696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8552301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of PA8552301A1 publication Critical patent/PA8552301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

EL INVENTO SE REFIERE A UN MEDICAMENTO PARA EL TRATAMIENTO Y LA MEJORA DE LA CALIDAD REPARADORA DEL SUEÑO EN PACIENTES QUE SUFREN DE INSOMNIO PRIMARIO, QUE COMPRENDE AL MENOS UN COMPUESTO SELECCIONADO ENTRE MELATONINA, OTROS AGENTES MELATONERGICOS, AGONISTAS DE LA MELATONINA Y ANTAGONISTAS DE LA MELATONINA EN UNA CANTIDAD EFICAZ DENTRO DE UN ENTORNO DE 0,0025 A 50 MG Y, OPTATIVAMENTE, OTRO U OTROS AGENTES TERAPEUTICAMENTE ACTIVOS.
PA20028552301A 2001-08-14 2002-08-09 Metodo para el tratamiento de insomnio primario PA8552301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL144900A IL144900A (en) 2001-08-14 2001-08-14 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Publications (1)

Publication Number Publication Date
PA8552301A1 true PA8552301A1 (es) 2003-06-30

Family

ID=11075696

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028552301A PA8552301A1 (es) 2001-08-14 2002-08-09 Metodo para el tratamiento de insomnio primario

Country Status (35)

Country Link
US (1) US8962024B2 (es)
EP (2) EP3103443B1 (es)
JP (1) JP2005501095A (es)
KR (1) KR20040032917A (es)
CN (1) CN100453078C (es)
AR (1) AR034975A1 (es)
AU (1) AU2002326114C1 (es)
BR (1) BR0211855A (es)
CA (1) CA2454699C (es)
CL (1) CL2002001701A1 (es)
CR (1) CR7271A (es)
CY (2) CY1118924T1 (es)
DK (2) DK3103443T3 (es)
EA (1) EA200400302A1 (es)
ES (2) ES2626591T3 (es)
GT (1) GT200200164A (es)
HK (1) HK1066161A1 (es)
HU (1) HU230786B1 (es)
IL (1) IL144900A (es)
IS (1) IS3004B (es)
JO (1) JO3446B1 (es)
LT (1) LT1441702T (es)
MX (1) MXPA04001372A (es)
NO (1) NO334788B2 (es)
NZ (1) NZ531318A (es)
PA (1) PA8552301A1 (es)
PE (1) PE20030331A1 (es)
PL (1) PL367872A1 (es)
PT (2) PT1441702T (es)
RU (1) RU2560840C2 (es)
SI (1) SI1441702T1 (es)
UA (1) UA87262C2 (es)
UY (1) UY27401A1 (es)
WO (1) WO2003015690A2 (es)
ZA (1) ZA200402005B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
CA2682200C (en) 2007-03-19 2015-01-13 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
WO2012103411A2 (en) * 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
EP3777842B1 (en) 2016-10-31 2024-12-11 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (es) 1972-05-19 1975-08-18 Bofors Ab
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ　ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5591768A (en) * 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
US5707652A (en) 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
EP0518468B1 (en) * 1991-05-09 1999-06-30 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0565296T3 (da) * 1992-04-07 1996-12-09 Neurim Pharma 1991 Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IL103411A (en) 1992-10-11 1996-11-14 Neurim Pharma 1991 Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
JP2781661B2 (ja) 1992-12-17 1998-07-30 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしての置換ピラゾール
CZ284157B6 (cs) 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
WO1995003043A1 (en) 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
NO981489L (no) * 1995-10-03 1998-05-22 Interneuron Pharma Blandinger av melatonin og analgetika samt anvendelser derav
AU3716997A (en) * 1996-07-17 1998-02-09 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5826408A (en) * 1997-05-08 1998-10-27 Riverwood International Corporation Rotary flap tucker for a cartoning machine
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
MXPA02005783A (es) * 2000-01-05 2003-10-14 Neurim Pharma 1991 Metodo y formulacion para el tratamiento de la resistencia a los antihipertensivos y otras afecciones asociadas.
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6703412B1 (en) * 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
AU2012316159A1 (en) 2011-09-27 2014-04-17 IBIS Medical, Inc. Intragastric implant devices

Also Published As

Publication number Publication date
NO20040087L (no) 2004-02-19
EP3103443A1 (en) 2016-12-14
WO2003015690A2 (en) 2003-02-27
AU2002326114B2 (en) 2007-03-08
CA2454699C (en) 2012-03-27
KR20040032917A (ko) 2004-04-17
EP1441702A4 (en) 2007-09-26
CL2002001701A1 (es) 2010-06-25
PL367872A1 (en) 2005-03-07
SI1441702T1 (sl) 2017-08-31
US8962024B2 (en) 2015-02-24
NO334788B1 (no) 2014-05-26
IL144900A0 (en) 2002-06-30
ES2882584T3 (es) 2021-12-02
CR7271A (es) 2004-05-17
AR034975A1 (es) 2004-03-24
CN100453078C (zh) 2009-01-21
HUP0401042A2 (hu) 2004-08-30
IL144900A (en) 2013-12-31
CY1118924T1 (el) 2018-01-10
NO334788B2 (no) 2014-05-26
RU2560840C2 (ru) 2015-08-20
JO3446B1 (ar) 2020-07-05
BR0211855A (pt) 2004-09-21
IS3004B (is) 2018-09-15
HUP0401042A3 (en) 2009-07-28
EP1441702A2 (en) 2004-08-04
UA87262C2 (uk) 2009-07-10
AU2002326114A1 (en) 2003-03-03
DK1441702T3 (en) 2017-06-06
PE20030331A1 (es) 2003-06-27
CY1124763T1 (el) 2022-07-22
IS7136A (is) 2004-01-30
LT1441702T (lt) 2017-06-12
WO2003015690A3 (en) 2003-09-25
WO2003015690B1 (en) 2004-03-11
HU230786B1 (en) 2018-05-02
UY27401A1 (es) 2003-02-28
CA2454699A1 (en) 2003-02-27
NZ531318A (en) 2005-08-26
EP3103443B1 (en) 2021-06-30
CN1541092A (zh) 2004-10-27
PT1441702T (pt) 2017-06-02
EA200400302A1 (ru) 2004-10-28
US20040248966A1 (en) 2004-12-09
MXPA04001372A (es) 2005-06-06
JP2005501095A (ja) 2005-01-13
HK1066161A1 (en) 2005-03-18
DK3103443T3 (da) 2021-08-30
RU2011131532A (ru) 2013-03-27
AU2002326114C1 (en) 2019-03-21
ZA200402005B (en) 2005-07-27
ES2626591T3 (es) 2017-07-25
PT3103443T (pt) 2021-08-12
EP1441702B1 (en) 2017-05-10
GT200200164A (es) 2003-09-26

Similar Documents

Publication Publication Date Title
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BG105575A (en) Method and agent for the treatment of cerebral ischaemia
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
GB0018527D0 (en) Composition
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
BG105534A (en) 5ht1 means and method for the treatment of migraine
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
JO2178B1 (en) Treatment of invasive diseases, using selected anti-PAR materials
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
HUP0101528A2 (hu) LHRH antagonisták és antiösztrogének alkalmazása termékenységi rendellenességek kezelésére
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
HN2002000218A (es) Metodo para el tratamiento del insomnio primario
AR042297A1 (es) Forma de dosificacion oral de liberacion inmediata
EE9700068A (et) Selegiliini kasutamine epileptiliste haiguste raviks
HUP0402625A2 (hu) Darifenacin hiperaktív hólyag által kiváltott sürgősség kezelésében való alkalmazásra